Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. reduced its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 6.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,380,428 shares of the company's stock after selling 167,663 shares during the quarter. T. Rowe Price Investment Management Inc. owned about 3.14% of Nurix Therapeutics worth $44,848,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its position in shares of Nurix Therapeutics by 85.2% during the third quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company's stock valued at $1,531,000 after buying an additional 31,352 shares during the last quarter. Jump Financial LLC purchased a new position in Nurix Therapeutics in the fourth quarter worth approximately $1,406,000. Barclays PLC lifted its position in shares of Nurix Therapeutics by 77.9% during the third quarter. Barclays PLC now owns 128,344 shares of the company's stock worth $2,884,000 after purchasing an additional 56,190 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in Nurix Therapeutics by 42.7% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock valued at $14,869,000 after purchasing an additional 235,971 shares during the last quarter. Finally, Affinity Asset Advisors LLC raised its stake in Nurix Therapeutics by 9.3% during the 4th quarter. Affinity Asset Advisors LLC now owns 940,083 shares of the company's stock valued at $17,711,000 after acquiring an additional 79,684 shares during the last quarter.

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,438 shares of the company's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $28,037.00. Following the completion of the sale, the chief financial officer now owns 39,922 shares in the company, valued at $459,103. This represents a 5.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Gwenn Hansen sold 3,377 shares of the firm's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the completion of the sale, the insider now directly owns 61,516 shares of the company's stock, valued at approximately $707,434. The trade was a 5.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,640 shares of company stock valued at $151,277 over the last ninety days. 7.40% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently weighed in on NRIX. Royal Bank of Canada lifted their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a report on Wednesday, January 29th. Stifel Nicolaus lowered their price objective on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. HC Wainwright reissued a "buy" rating and set a $36.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Morgan Stanley raised their price target on Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a research note on Monday, February 3rd. Finally, JPMorgan Chase & Co. cut their target price on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Three equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $30.44.

Nurix Therapeutics Stock Up 1.5 %

NRIX traded up $0.17 during trading on Friday, reaching $11.33. The stock had a trading volume of 247,721 shares, compared to its average volume of 886,517. The stock has a 50 day moving average of $12.13 and a two-hundred day moving average of $18.08. The firm has a market capitalization of $863.68 million, a price-to-earnings ratio of -3.92 and a beta of 2.23. Nurix Therapeutics, Inc. has a 1-year low of $8.18 and a 1-year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.05. The company had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same quarter in the previous year, the company posted ($0.76) EPS. On average, research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.